Royal Philips Reports Q2 Sales Growth, Upgrades 2026 Outlook

What happened

Royal Philips delivered second-quarter sales of €4.4 billion, representing 4% comparable growth across all business segments, exceeding the analyst consensus of €4.26 billion. The company's adjusted EBITA margin reached 16.4% in Q2, significantly above the expected 12.1%, driven partly by a 4.2% benefit from U.S. tariff refunds. Philips, which generates over 40% of sales in North America, completed most of its U.S. tariff refund process during the quarter, becoming one of the first European companies to report these rebates.

Why it matters

The earnings beat and raised guidance signal improved operational performance and meaningful financial relief from tariff refunds. The upgraded full-year outlook-with adjusted EBITA margin now expected at 13.5%-14.0% (up from 12.5%-13.0%) and free cash flow at €1.5-1.7 billion (up from €1.3-1.5 billion)-provides investors with greater confidence in Philips' profitability trajectory through 2026. The tariff refunds directly strengthen cash generation and margins, reducing a significant cost burden that had weighed on the company's North American operations.

Bigger picture

Philips' tariff refund disclosure may signal a broader wave of rebates for European healthcare technology companies operating in the U.S. market, potentially reshaping margin expectations across the sector. The company continues navigating macroeconomic headwinds including inflation, but the tariff relief provides a cushion against cost pressures. Strong growth across all business segments suggests resilient demand for Philips' healthcare technology portfolio despite broader economic uncertainty.

What to watch

Investors should monitor whether other European medtech companies announce similar U.S. tariff refunds, which could shift sector-wide margin forecasts. Key upcoming signals include Philips' ability to sustain comparable sales growth momentum in subsequent quarters, progress on managing inflationary costs, and whether the company can maintain its upgraded 13.5%-14.0% EBITA margin range without one-time tariff benefits. Free cash flow execution toward the raised €1.5-1.7 billion target will be critical for validating the improved financial outlook.